You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 8,455,539

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,455,539

Title:	CCI-779 concentrate formulations
Abstract:	This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.
Inventor(s):	Rubino; Joseph T. (Towaco, NJ), Siskavich; Victoria (Lyon Mountain, NY), Harrison; Maureen M. (Sugar Loaf, NY), Gandhi; Pooja (Highland Mills, NY)
Assignee:	Wyeth LLC (Madison, NJ)
Application Number:	13/651,623
Patent Claims:	1. A CCI-779 cosolvent concentrate comprising: (i) about 25 mg/mL of CCI-779; (ii) about 40% w/v of dehydrated ethanol; (iii) about 50% w/v of propylene glycol; (iv) about 0.075% w/v of d,1-.alpha.-tocopherol; and (v) about 0.0025% w/v of citric acid. 2. The CCI-779 cosolvent concentrate according to claim 1, which is diluted at a ratio of 1:1.5 concentrate to diluent to form the parenteral formulation. 3. A CCI-779 cosolvent concentrate comprising: (i) about 25 mg/mL of CCI-779; (ii) 39% w/v of dehydrated ethanol; (iii) about 50% w/v of propylene glycol; (iv) about 0.075% w/v of d,1-.alpha.-tocopherol; and (v) about 0.0025% w/v of citric acid. 4. The CCI-779 cosolvent concentrate according to claim 3, which is diluted at a ratio of 1:1.5 concentrate to diluent to form the parenteral formulation. 5. A CCI-779 cosolvent concentrate comprising: (i) about 25 mg/mL of CCI-779; (ii) about 40% w/v of dehydrated ethanol; (iii) 51% w/v of propylene glycol; (iv) about 0.075% w/v of d,1-.alpha.-tocopherol; and (v) about 0.0025% w/v of citric acid. 6. The CCI-779 cosolvent concentrate according to claim 5, which is diluted at a ratio of 1:1.5 concentrate to diluent to form the parenteral formulation. 7. A CCI-779 cosolvent concentrate comprising: (i) about 25 mg/mL of CCI-779; (ii) about 39% w/v of dehydrated ethanol; (iii) 51% w/v of propylene glycol; (iv) about 0.075% w/v of d,1-.alpha.-tocopherol; and (v) about 0.0025% w/v of citric acid. 8. The CCI-779 cosolvent concentrate according to claim 7, which is diluted at a ratio of 1:1.5 concentrate to diluent to form the parenteral formulation.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.